Last reviewed · How we verify
Novavax Trivalent vaccine
Novavax Trivalent vaccine is a Biologic drug developed by Novavax. It is currently in Phase 2 development.
At a glance
| Generic name | Novavax Trivalent vaccine |
|---|---|
| Sponsor | Novavax |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (PHASE3)
- A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Novavax Trivalent vaccine CI brief — competitive landscape report
- Novavax Trivalent vaccine updates RSS · CI watch RSS
- Novavax portfolio CI
Frequently asked questions about Novavax Trivalent vaccine
What is Novavax Trivalent vaccine?
Novavax Trivalent vaccine is a Biologic drug developed by Novavax.
Who makes Novavax Trivalent vaccine?
Novavax Trivalent vaccine is developed by Novavax (see full Novavax pipeline at /company/novavax).
What development phase is Novavax Trivalent vaccine in?
Novavax Trivalent vaccine is in Phase 2.
Related
- Manufacturer: Novavax — full pipeline
- Compare: Novavax Trivalent vaccine vs similar drugs
- Pricing: Novavax Trivalent vaccine cost, discount & access